One of the drug studies carried out for Alzheimer’s disease, which affects millions of people, their families and health workers around the world and turns their lives into a nightmare, has given hope to everyone with the positive test results…
So far many medicine manufacturer, which affects approximately 55 million people worldwide and causes our brain to deplete day by day. Alzheimer’s He tried to find an effective treatment for his illness and failed.
The latest breakthrough in the treatment of Alzheimer’s, which devastates not only those with the disease, but also their families and caregivers, seems to be a beacon of hope for countless people.
EFFECTIVE IN THE EARLY STAGE OF THE DISEASE
An experimental Alzheimer’s drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a trial with multiple patients in the early stages of the disease.
While the statement said that this is a rare win in disease-related studies, the study will also return as a big win to pharmaceutical companies that have produced drugs that have not been successful before.
“It’s not a huge effect, but a positive one,” said Ronald Petersen, director of the Mayo Clinic Alzheimer’s Research Center, when speaking of the Eisai-Biogen drug trial results announced.
SLOWS THE PROGRESS OF THE DISEASE
The drug slowed disease progression by 27 percent compared to a placebo, meeting the study’s main goal and potentially giving hope to patients and their families desperate for an effective treatment.
Despite the race to halt the progression of Alzheimer’s, the number of Americans living with the disease is expected to nearly double to 13 million by 2050, according to the Alzheimer’s Association.
Globally, this figure is projected to reach 139 million by 2050 without effective treatment.
THIS THEORY HAS BEEN RESPECTED FOR A LONG TIME
Eisai said the results of the study of 1,800 patients proved the long-held theory that removing sticky deposits of a protein called amyloid beta from the brains of early Alzheimer’s patients could delay the progression of the mind-debilitating disease.
It aims for the drug to be fully approved and commercialized in the United States, Europe and Japan by the end of 2023, the company’s CEO, Haruo Naito, told reporters in Tokyo.
“VERY EARLY DAYS”
Speaking about the drug called lecanemab, neurologist Dr. “If you can slow a disease by almost 30 percent, that’s a great result,” said Jeff Cummings.
Director of a clinical research unit at the University of Copenhagen, Dr. Kristian Steen Frederiksen said that although the top-ranking results for Lecanemab are convincing, it is still ‘very early days’ to determine whether the effects are clinically meaningful and underlined that Alzheimer’s is an ‘extremely complex disease. It is unlikely to be a significant factor,” he said.